Marek Śmiłowski

机构：Medical University of Silesia

发表论文 28 篇 · 总被引 1257 次 · h-index 7

代表论文

• Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial (2021 · The Lancet Neurology · 被引 721)
• Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study (2023 · The Lancet Neurology · 被引 272)
• Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study (2025 · The Lancet Neurology · 被引 95)
• Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+) (2024 · Neurotherapeutics · 被引 56)
• Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study (2024 · Therapeutic Advances in Neurological Disorders · 被引 45)
• Validation of the Polish version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (2020 · Neurologia i Neurochirurgia Polska · 被引 25)